SLC5A2 and urinary tract infection: Thus, the Food and Drug Administration raised an alarm for severe urinary tract infections associated with SGLT2 inhibitors based on a limited number of reported cases; nevertheless, data from large randomized controlled trials showed no significant difference between SGLT2 inhibitors and the placebo.